2 days Ago By Defense World Staff
KLP Kapitalforvaltning AS acquired a new position in ImmunityBio, Inc. ( NASDAQ:IBRX – Free Report ) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 22,100 shares of the company’s stock, valued at approximately $57,000.
Several other institutional investors have also recently made changes to their positions in IBRX. State Street Corp boosted its stake in ImmunityBio by 10.1% in the 3rd quarter.
State Street Corp now owns 8,654,460 shares of the company’s stock worth $32,195,000 after purchasing an additional 790,408 shares during the period. Clearwater Capital Advisors LLC grew its stake in ImmunityBio by 75.4% during the fourth quarter.
Clearwater Capital Advisors LLC now owns 846,419 shares of the company’s stock valued at $2,167,000 after acquiring an additional 363,870 shares in the last quarter. Barclays PLC increased its holdings in ImmunityBio by 127.4% in the 3rd quarter.
Barclays PLC now owns 361,036 shares of the company’s stock valued at $1,344,000 after acquiring an additional 202,248 shares during the last quarter. XTX Topco Ltd lifted its position in shares of ImmunityBio by 309.4% in the third quarter.
XTX Topco Ltd now owns 92,910 shares of the company’s stock worth $346,000 after buying an additional 70,215 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new position in ImmunityBio during the 4th quarter valued at approximately $172,000.
Hedge funds and other institutional investors own 8.58% of the company’s stock. Analyst Upgrades and Downgrades IBRX has been the topic of several recent research reports.
HC Wainwright reaffirmed a “buy” rating and set a $8.00 price objective on shares of ImmunityBio in a report on Thursday, March 13th. BTIG Research initiated coverage on shares of ImmunityBio in a research note on Friday, January 10th.
They set a “buy” rating and a $6.00 price target on the stock. Finally, D.
Boral Capital reissued a “buy” rating and issued a $30.00 price objective on shares of ImmunityBio in a research note on Wednesday. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock.
According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $12.19.
ImmunityBio Stock Up 6.9 % IBRX stock opened at $2.63 on Friday.
ImmunityBio, Inc. has a twelve month low of $2.28 and a twelve month high of $10.
53. The stock has a market capitalization of $2.24 billion, a price-to-earnings ratio of -2.
86 and a beta of 0.51. The firm’s fifty day simple moving average is $3.
01 and its two-hundred day simple moving average is $3.54. ImmunityBio ( NASDAQ:IBRX – Get Free Report ) last issued its quarterly earnings results on Monday, March 3rd.
The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.
11. The firm had revenue of $7.55 million for the quarter, compared to the consensus estimate of $8.
74 million. As a group, equities research analysts expect that ImmunityBio, Inc. will post -0.
92 EPS for the current year. ImmunityBio Profile ( Free Report ) ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.
Further Reading Five stocks we like better than ImmunityBio How to Find Undervalued Stocks JPMorgan is a Buy, if You Can Handle The Volatility How to Use the MarketBeat Excel Dividend Calculator United States Steel’s Crash: An Unmissable Buying Opportunity Which Wall Street Analysts are the Most Accurate? Rocket Lab Stock: Weathering the Storm, Time for a Comeback? Want to see what other hedge funds are holding IBRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ImmunityBio, Inc. ( NASDAQ:IBRX – Free Report ).
Receive News & Ratings for ImmunityBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunityBio and related companies with MarketBeat.com's FREE daily email newsletter ..
